ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Alnylam and Sanofi report RNAi success

by Michael McCoy
September 25, 2017 | APPEARED IN VOLUME 95, ISSUE 38

Patisiran, an RNA interference drug being developed by Alnylam and Sanofi, met its primary goals in a Phase III study as a treatment for hereditary ATTR amyloidosis, a rare genetic disease. Alnylam plans to file a New Drug Application later this year. “We are proud to report the first-ever positive Phase III results for an RNAi therapeutic,” says Alnylam CEO John Maraganore. Alnylam’s stock price soared more than 20% on the news. The firm earlier experienced setbacks for two other RNAi drugs, revusiran and fitusiran.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment